JP Morgan Chase’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-10
| Closed | -$15 | – | 7745 |
|
|
2024
Q2 | $15 | Sell |
10
-171
| -94% | -$1.3K | ﹤0.01% | 7186 |
|
|
2024
Q1 | $1.59K | Sell |
181
-30
| -14% | -$231 | ﹤0.01% | 6603 |
|
|
2023
Q4 | $1.23K | Hold |
211
| – | – | ﹤0.01% | 6807 |
|
|
2023
Q3 | $1.23K | Sell |
211
-17
| -7% | -$189 | ﹤0.01% | 6617 |
|
|
2023
Q2 | $1.33K | Buy |
228
+20
| +10% | +$228 | ﹤0.01% | 6417 |
|
|
2023
Q1 | $2K | Buy |
208
+20
| +11% | +$266 | ﹤0.01% | 6451 |
|
|
2022
Q4 | $2K | Buy |
+188
| New | +$2.79K | ﹤0.01% | 6350 |
|
|
2022
Q3 | – | Sell |
-228
| Closed | -$4K | – | 6920 |
|
|
2022
Q2 | $4K | Sell |
228
-145
| -39% | -$3.63K | ﹤0.01% | 6215 |
|
|
2022
Q1 | $14K | Sell |
373
-293
| -44% | -$10.5K | ﹤0.01% | 6146 |
|
|
2021
Q4 | $24K | Sell |
666
-80
| -11% | -$4.21K | ﹤0.01% | 6172 |
|
|
2021
Q3 | $56K | Sell |
746
-174
| -19% | -$12.4K | ﹤0.01% | 5804 |
|
|
2021
Q2 | $81K | Sell |
920
-54
| -6% | -$5.14K | ﹤0.01% | 5609 |
|
|
2021
Q1 | $111K | Buy |
974
+15
| +2% | +$1.66K | ﹤0.01% | 5348 |
|
|
2020
Q4 | $41K | Buy |
959
+19
| +2% | +$703 | ﹤0.01% | 5203 |
|
|
2020
Q3 | $34K | Buy |
940
+22
| +2% | +$975 | ﹤0.01% | 5051 |
|
|
2020
Q2 | $74K | Buy |
918
+7
| +0.8% | +$641 | ﹤0.01% | 4681 |
|
|
2020
Q1 | $47K | Sell |
911
-11
| -1% | -$1K | ﹤0.01% | 4748 |
|
|
2019
Q4 | $84K | Hold |
922
| – | – | ﹤0.01% | 4961 |
|
|
2019
Q3 | $95K | Buy |
922
+72
| +8% | +$15.6K | ﹤0.01% | 4922 |
|
|
2019
Q2 | $240K | Sell |
850
-18
| -2% | -$6.34K | ﹤0.01% | 4591 |
|
|
2019
Q1 | $403K | Buy |
868
+1
| +0.1% | +$388 | ﹤0.01% | 4308 |
|
|
2018
Q4 | $255K | Buy |
867
+58
| +7% | +$13.9K | ﹤0.01% | 4476 |
|
|
2018
Q3 | $118K | Buy |
809
+10
| +1% | +$1.83K | ﹤0.01% | 4887 |
|
|
2018
Q2 | $156K | Sell |
799
-10
| -1% | -$1.84K | ﹤0.01% | 4674 |
|
|
2018
Q1 | $118K | Buy |
809
+52
| +7% | +$10.2K | ﹤0.01% | 4542 |
|
|
2017
Q4 | $179K | Buy |
757
+189
| +33% | +$39.3K | ﹤0.01% | 4460 |
|
|
2017
Q3 | $120K | Buy |
568
+465
| +451% | +$85.6K | ﹤0.01% | 4251 |
|
|
2017
Q2 | $10K | Buy |
+103
| New | +$16.3K | ﹤0.01% | 4664 |
|
|
2014
Q4 | – | Sell |
-3
| Closed | -$43K | – | 4398 |
|
|
2014
Q3 | $43K | Buy |
+3
| New | +$38.4K | ﹤0.01% | 4120 |
|
Other funds holding CSCI
JP Morgan Chase's CSCI Position: Q3 2024 in Review
JP Morgan Chase sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2024, closing a stake of 10 shares — an estimated $15 sold.
JP Morgan Chase first reported a position in CSCI in Q3 2014 and held it in 29 quarters. The position peaked at $403K in Q1 2019. 9 funds tracked by Wall St. Rank hold CSCI as of Q3 2024.
- JP Morgan Chase reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- JP Morgan Chase sold 10 COSCIENS Biopharma Inc. Common Stock shares in Q3 2024, an estimated $15.
- JP Morgan Chase first reported a position in COSCIENS Biopharma Inc. Common Stock in Q3 2014 and held it in 29 quarters.
- JP Morgan Chase's COSCIENS Biopharma Inc. Common Stock position peaked at $403K in Q1 2019.
- 9 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2024.
Based on JP Morgan Chase's 13F filing for Q3 2024, filed 8 Nov 2024.